BRANDL TALOS advises lead investor on EUR 18m Series A financing round of Ribbon Biolabs

Press release • Venture Capital & Start Ups from Roman Rericha, Stephan Strass

Ribbon Biolabs GmbH, a DNA synthesis company, has completed a EUR 18m Series A financing round led by Hadean Ventures with participation from, amongst others, Lansdowne Partners, Helicase Venture and existing investors IST cube and tecnet equity. A BRANDL TALOS-deal team led by Roman Rericha and Stephan Strass advised the lead investor, Hadean Ventures, on this financing round.

Ribbon Biolabs was founded in 2018 to redefine the potential of synthetic DNA. The funds will be used for the commercialization of the company’s DNA synthesis technology, which uses an innovative approach integrating combinatorial optimization algorithms to duie the automated enzymatic assembly of DNA. This includes the set-up of production facilities with key technology partners and the preparation for expansion into the US market.

» We are excited to support Ribbon Biolabs on its mission to fully automate long DNA synthesis. It was a pleasure working with Roman, Stephan and their team on this transaction and we look very much forward to many further projects with them. «

Walter Stockinger, Managing Partner at Hadean Ventures

The BRANDL TALOS-deal team was led by Roman Rericha and Stephan Strass and further consisted of Elena Ciresa and Céline Dobnikar. Ribbon Biolabs was advised by Herbst Kinsky (Carl Walderdorff and Christina Bernhart).

The team

Roman Rericha

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 5
            [name] => Attorney at Law
            [slug] => attorney-at-law
            [term_group] => 0
            [term_taxonomy_id] => 5
            [taxonomy] => category
            [description] => 
            [parent] => 0
            [count] => 17
            [filter] => raw
        )

    [1] => WP_Term Object
        (
            [term_id] => 4
            [name] => Partner
            [slug] => partner
            [term_group] => 0
            [term_taxonomy_id] => 4
            [taxonomy] => category
            [description] => Partner
            [parent] => 0
            [count] => 8
            [filter] => raw
        )

)

Partner / Fund Formation, Venture Capital & Start Ups, Corporate Law & Transactions

Roman represents clients in complex cross-border M&A and private equity transactions. Austrian and international venture capital funds regularly turn to him for assisting with investments in Austria. His expert advice also guides start-ups through large-scale financing rounds.

University of Vienna, Faculty of Law (Mag. iur. 2005),
Faculty of Business, Economics and Statistics, (Mag. rer.soc.oec. 2007)

Stephan Strass

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 5
            [name] => Attorney at Law
            [slug] => attorney-at-law
            [term_group] => 0
            [term_taxonomy_id] => 5
            [taxonomy] => category
            [description] => 
            [parent] => 0
            [count] => 17
            [filter] => raw
        )

    [1] => WP_Term Object
        (
            [term_id] => 4
            [name] => Partner
            [slug] => partner
            [term_group] => 0
            [term_taxonomy_id] => 4
            [taxonomy] => category
            [description] => Partner
            [parent] => 0
            [count] => 8
            [filter] => raw
        )

)

Partner / Venture Capital & Start Ups, Corporate Law & Transactions, BioTech & Lifescience

Stephan advises innovative start-ups, institutional and strategic investors and other companies on acquisitions, financing rounds, joint ventures and exit transactions with a focus on highly regulated industries such as life sciences, biotech and leisure & entertainment. He further specializes in commercial transactions in the life science and biotech sector, including university spin-offs, strategic collaborations, patent and technology license agreements and IP purchase transactions.

He has co-authored commentaries on the EU Merger Act and the Investment Fund Act, and is the author of many academic publications.

University of Vienna, Faculty of Law (Mag. iur. 2015)
Harvard Law School, Master of Laws (LL.M. 2019)

Latest insights into
Venture Capital & Start Ups

BRANDL TALOS advised Springtime and its Founders on growth equity investment from Scottish Equity Partners

Press release • Venture Capital & Start Ups from Roman Rericha, Adrian Zuschmann, Joseph Gstöttner, Daniel Habich

Springtime Technologies, a leading provider of AI-driven accounts payable automation software, has received a significant growth equity investment from Scottish Equity Partners (SEP), one of Europe's most respected growth equity firms. This strategic partnership marks an exciting new chapter in Springtime's 20-year journey of empowering enterprises with innovative solutions for financial operations.

BRANDL TALOS advises Sportradar on $ 30 million acquisition of XLMedia PLC’s North American business

Press release • Venture Capital & Start Ups from Thomas Talos, Stephan Strass

BRANDL TALOS advised its longstanding client Sportradar on the acquisition of the key assets of XLMedia PLC’s North American business.

BRANDL TALOS advised DirectSens on the sale of its market-leading LactoSens® biosensor technology to Kerry Group

Press release • Venture Capital & Start Ups from Roman Rericha, Stephan Strass

Founded in 2013 in Vienna by Christoph Sygmund, Roman Kittl, Roland Ludwig, Wolfgang Harreither and Alfons Felice as a spinoff of BOKU University, DirectSens specializes in developing biosensors, including LactoSens®, a rapid lactose detection tool. The acquisition of LactoSens® by Kerry Group reflects DirectSens' success in developing cutting-edge biosensor solutions and represents a move by Kerry Group to complement its offering in lactase enzymes.